No description
-
2018 (v1)PublicationUploaded on: May 12, 2023
-
2020 (v1)Publication
Background: The association between treatment-related lymphopenia in multiple sclerosis, drug efficacy and the risk of infections is not yet fully understood. Objective: The objective of this study was to assess whether lymphopenia is associated with short-term treatment response and infection rate in a real-life multiple sclerosis population...
Uploaded on: April 14, 2023 -
2021 (v1)Publication
The management of multiple sclerosis patients with persistent disease activity under alemtuzumab treatment is not established yet. Concerns have been raised on the safety of autologous haematopoietic stem cell transplantation (aHSCT) after alemtuzumab treatment because of the risk of serious infectious adverse events. We report short-term...
Uploaded on: April 14, 2023